ORIC实时信号 | 通过Getagraph.com最大化利润

购买 107724 min ago

@ $11.31

发出时间: 15 Feb 2024 @ 03:07

回报率: -26.34%

上一信号: Feb 14 - 02:45

上一信号: 出售

回报率: -1.65 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:31):

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States...

Stats
今日成交量	43 737.00
平均成交量	570 877
市值	561.63M
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $-0.440 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.25
ATR14	$0.0420 (0.50%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Chacko Jacob	Sell	40 000	Common Stock
2024-02-06	Chacko Jacob	Sell	13 958	Common Stock
2024-02-07	Chacko Jacob	Sell	26 042	Common Stock
2024-01-02	Multani Pratik S	Buy	180 000	Stock Option (right to buy)
2024-01-02	Multani Pratik S	Buy	30 000	Restricted Stock Unit

INSIDER POWER
54.58
Last 99 transactions
Buy: 6 373 472 \| Sell: 3 807 004

音量相关性

長: -0.14 (neutral)

短: -0.98 (very strong negative)

Signal:(54.158) Neutral

Oric Pharmaceuticals Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Oric Pharmaceuticals Inc 相关性 - 货币/商品

0.24
( neutral )

0.05
( neutral )

0.00
( neutral )

-0.05
( neutral )

0.77
( moderate )

-0.34
( neutral )

Oric Pharmaceuticals Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2023
营收:	$0
毛利润:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2022
营收:	$0
毛利润:	$-966 000 (0.00 %)
EPS:	$-2.31

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.07

Financial Reports:

No articles found.

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.